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At a Glance Commentary: Scientific Knowledge on the Subject 
Primary Ciliary Dyskinesia is a genetically heterogeneous chronic condition.  Early diagnosis 
is key to attenuating disease progression by implementation of appropriate medical 
management.  Currently diagnosis requires expensive and complex equipment 
 
What This Study Adds to the Field 
This study validates the clinical use of a panel of commercially available antibodies to 
diagnose Primary Ciliary Dyskinesia by immunofluorescence, a simpler, more widely 
available, cost effective alternative to current confirmatory diagnostic tests. 
Immunofluorescence is a useful diagnostic test for PCD, reduces the need for repeat biopsies, 
and improves turnaround time without compromising diagnostic accuracy. 
 
"This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org" 
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ABSTRACT 
Rationale Diagnosis of primary ciliary dyskinesia is by measuring ciliary beat frequency and 
pattern by video microscopy and ciliary ultrastructure by electron microscopy; equipment and 
expertise is not widely available. Fluorescent antibodies to ciliary proteins are widely used to 
validate genetic studies in many settings, but diagnostic utility in this disease has not been 
systematically evaluated. 
 
Objectives  Determine the sensitivity and specificity of a panel of fluorescent labelled 
antibodies as a diagnostic tool for primary ciliary dyskinesia. 
 
Methods Immunofluorescent labelling of nasal brushings from 35 patients with primary 
ciliary dyskinesia, and 386 patients referred with symptoms suggestive of the disease, using 
six commercially available antibodies. Each was assessed on a smear slide in a double label 
with acetylated tubulin to demonstrate the presence of cilia. The results were compared to 
diagnostic outcome by conventional pathways. 
 
Measurements and Main Results Immunofluorescence correctly identified primary ciliary 
dyskinesia in the discovery cohort. In the diagnostic accuracy study immunofluorescence 
successfully identified 22 of 25 patients diagnosed with primary ciliary dyskinesia and all 252 
in whom the diagnosis was excluded, positive predictive value 1.0 and negative predictive 
value 0.01. Sensitivity was 88%, specificity was 100%. Immunofluorescence additionally 
correctly diagnosed 55% (39) of cases which were inconclusive using the standard diagnostic 
protocol. Immunofluorescence results were available within 14 days, costing $187 per sample 
compared to electron microscopy which took 27 days and cost $1452. 
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Conclusions Immunofluorescence is a sensitive and highly specific diagnostic test for 
primary ciliary dyskinesia, and can improve the speed and availability of diagnostic testing.  
 
Abstract word count: 252 
Key words: Cilia, Electron microscopy, Antibody 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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Primary Ciliary Dyskinesia (PCD) affects approximately 1 in 15,000 of the population.  
Manifestations are caused by defective ciliary beating and reduced mucociliary clearance. 
Diagnosis is frequently delayed, and delay is associated with significant impairment of lung 
function. Diagnostic delay is related to two factors: the non-specificity of symptoms (cough, 
rhinitis) and the lack of an easy and widely available diagnostic test for the condition.  [1] 
 
The diagnosis pathway for PCD includes measurement of nasal nitric oxide, followed by a 
nasal brush biopsy for light and electron microscopy. Light microscopic assessment of ciliary 
function is by high speed video analysis of the frequency and pattern (waveform) of cilia 
movement on live cells. Electron microscopy allows visualisation of the ultrastructure of cilia 
and can often provide a definitive diagnosis [1]. All tests require sophisticated equipment and 
considerable expertise, and in consequence are only available in very few centres. Genetic 
testing for PCD is also increasingly used, but there are at least 200 potential genes which 
arewidely scattered through the karyotype. To date, more than 30 disease-associated 
mutations have been identified, which are estimated to account for 60-65% of known cases 
[2,3]. 
 
Immunofluorescence allows specific antibodies with fluorescent tags indirectly to image 
target proteins by fluorescent or confocal microscopy.  The use of double labelling allows the 
co-localisation of proteins to be determined. Immunofluorescence for the diagnosis of PCD 
was first described in 2005 and was subsequently recommended in the ERS expert consensus 
statement for diagnosis and treatment of PCD [4,5]. Despite this recommendation limited 
commercial availability of validated antibodies and lack of evidence for the diagnostic 
accuracy of the technique has limited its use.  Immunofluorescence has been used extensively 
in PCD research in confirming protein absence due to genetic mutations. A number of 
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antibodies to proteins defective in PCD have been developed and validated. These include 
DNAH5 (an outer dynein arm heavy chain) [4,6], DNALI1 (an inner dynein arm light 
chain)[6,7], GAS8 (a component of the nexin dynein regulatory link) [7] and RSPH4A, 
RSPH9 and RSPH1 (components of the radial spoke)[8]. These antibodies represent the four 
key ultrastructural abnormalities detected by electron microscopy which are the end products 
of multiple gene defects (table 1 and figure 1). It can be seen that absence or mislocation of a 
single protein allows the effects of mutations in multiple genes to be detected. We 
hypothesised that immunofluorescence using a panel of antibodies would be a sensitive and 
specific diagnostic test for PCD, and aimed to assess this in a large cohort of patients with 
possible PCD referred for diagnostic testing. 
 
METHODS 
Subjects 
Discovery cohort- Nasal brushings were analysed from a cohort of 35 patients with a known 
PCD ultrastructural defect. 
Diagnostic accuracy cohort- Sequential nasal brushings were analysed from 386 patients 
referred to the Royal Brompton Hospital for PCD diagnosis.  Referrals were due to symptoms 
suggestive of PCD such as situs inversus, neonatal respiratory distress, bronchiectasis, 
recurrent chest infections, rhinosinusitis and otitis media. 
 
Diagnosis of PCD 
All patients underwent a standardised diagnostic protocol regularly audited across the 3 UK 
PCD centres [5].  
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1. Assessment for symptoms suggestive of PCD (n= 378/386; 8 external samples had a 
limited clinical history).  
2. Nasal Nitric Oxide measurement – In children >4 years. Two readings from each nostril 
were taken during a breath hold manoeuvre using a chemiluminescent analyser LR2000 
(Logan Research, Rochester, UK) [9] (n= 129/386) 
3. High speed video microscopy for cilia beat frequency and ciliary beat pattern measured at 
37ºC using a 100x objective [10] (n=386/386) 
4. Quantitative transmission electron microscopy of ciliary ultrastructure [11] (n=208/386) 
5. Air liquid interface culture of difficult samples and repeat light and electron microscopy 
[12] (n=115/386) 
6. Genotyping from blood sample in patients with likely PCD based on other investigations 
(n=16/386) 
 
In the absence of an established gold standard, a diagnosis of PCD was made following a 
review of clinical and laboratory findings in a monthly multidisciplinary meeting (MDT) lead 
by a consultant clinician with expertise in PCD 
 
Experimental methods 
Methodological details are provided in the online data supplement [4]. All slides were double 
labelled with acetylated alpha tubulin (T7451, Sigma Aldrich) in order to visualise cilia. 
Antibodies of interest were used in a two step protocol. All nasal brushings were assessed for 
Panel 1: DNAH5 (HPA037470), DNALI1 (HPA053129), RSPH4A (HPA031196). A second 
round of antibodies were used in selected cases. Panel 2: RSPH9 (HPA031703), RSPH1 
(HPA017382) or GAS8 (HPA041311) 
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Slides were scanned under a fluorescent microscope for ciliated cells at x40 magnification to 
identify acetylated tubulin. In each ciliated cell, the co-localised ciliary protein of interest was 
assessed in a second channel. If there was visual co-localisation of the antibody label with 
acetylated tubulin the target protein was considered present. If more than seven of ten ciliated 
cells were clearly labelled the sample was considered normal for that protein.  PCD was 
defined as at least ten of ten ciliated cells with absent or partial staining of the target protein 
and was repeated on a duplicate slide for confirmation. Insufficient and inconclusive slides 
were repeated. If the second assessment was normal the second assessment was included in 
results (n=71). 
 
Statistical methods 
The subject number was based on a 10% prevalence of PCD in the population tested, and a 
sensitivity of 85%, obtained from pilot data during antibody testing. Power calculations 
predicted 271 patients with a confirmed diagnosis of ‘PCD’ or ‘Non-PCD’ would be required 
to predict sensitivity and specificity with 95% confidence. Results were analysed in graph 
pad prism 5 and a p value <0.05 considered significant. Diagnostic sensitivity and specificity 
was calculated for immunofluorescence and compared to the MDT diagnosis of PCD. This 
calculation included only samples in which a positive or negative conclusion was reached. 
Exclusions are shown in Figure 2.  
 
ETHICS 
This study was conducted according to the recommendations of the Declaration of Helsinki.  
The protocol was approved by the Hounslow and Hillingdon ethical review committee 
(08/H0709/73).Written consent was obtained from subjects or their parent/guardian.  
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RESULTS 
Immunofluorescence can be used to confirm a diagnosis of PCD 
Antibodies were tested on nasal brushings from a discovery cohort of 35 patients with PCD 
with a confirmed ultrastructural ciliary defect.  Results shown in table 2 demonstrated 
complete agreement between absence of structure by electron microscopy and absence of 
associated protein by immunofluorescence. 
 
Diagnostic accuracy of immunofluorescence in the validation cohort 
The immunofluorescence technique successfully demonstrated an absence of target proteins 
from the axoneme in 22 of 25 patients with a MDT diagnosis of PCD. Normal results were 
obtained in all 252 patients who did not have PCD.  
 
Figure 2 shows an example of immunofluorescent staining of ciliated epithelial cells from 
two patients who were ‘PCD-positive’ and a patient who was ‘PCD-negative’. The IF 
protocol had a positive predictive value (PPV) of 1.0 and negative predictive value (NPV) of 
0.01 in this population.  Sensitivity was 88% and specificity 100%.  
 
Results of the diagnostic tests and immunofluorescence tests are shown in tables 3 and 4. 
Immunofluorescence identified all patients who had an identifiable ultrastructural defect. 
Sensitivity and specificity of the test was the same as that of electron microscopy. 
 
Three patients who were ‘PCD- positive’ were not identified using the immunofluorescence 
protocol and were examined in closer detail.  Genetic tests in two patients showed mutations 
in DNAH11. Both patients had a beat pattern consistent with this defect (hyperfrequent, stiff 
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and static) on more than one biopsy and nasal NO <77nl/min. One patient had 
consanguineous parents and was homozygous for a nonsense mutation (c.3380G>A , 
p.Trp1127*) the other had heterozygous nonsense changes (c.5506C>T , p.Arg1836* and 
c.5636T>A p.Leu1879*) .  The third individual was also from consanguineous parentage and 
was homozygous for a frame shift mutation in the HYDIN gene (c.2196dupT, p.Y372fs). The 
ultrastructure from these three patients was considered normal by standard electron 
microscopy. Electron tomography from the patient with the HYDIN mutation showed absence 
of the c2b central pair projection [16]. 
 
Insufficient and inconclusive samples 
 
Immunofluorescence as part of the diagnostic pathway could reduce the requirement for 
repeat nasal brushing.  
In 71 patients a conclusive MDT diagnosis was not made on first sampling due to insufficient 
tissue for light and/or electron microscopy. The immunofluorescence protocol was able to 
produce a definitive result for 55% (39) of these cases. Two of these cases showed an absence 
of DNAH5 by immunofluorescence and were confirmed subsequently on a repeat biopsy as 
an outer dynein arm defect by electron microscopy.  The remaining 37 samples, in which 
immunofluorescence testing was normal, were confirmed ‘PCD-negative’ on second testing 
either by repeat nasal brushing (n=31) or by culturing the original sample at air liquid 
interface (n=6).  
 
Insufficient and inconclusive results by immunofluorescence 
In 42 samples in which a MDT diagnosis was made there were not enough cells for 
immunofluorescence. In a further 32 samples in which a MDT diagnosis was made the 
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immunofluorescence result for one or more antibody was inconclusive on more than one 
occasion. Sixty nine of these patients (represented by 71 samples) did not have PCD, 
however, two were diagnosed with PCD at the MDT meeting. One of these two patients 
yielded a sample which was insufficient for immunofluorescence, light microscopy and 
electron microscopy but found to have a mutation in the CCNO gene (c.258_262dupGGCCC, 
p.Gln88Argfs*8). This patient was related to a previously genetically characterised family 
with reduced generation of multiple motile cilia (14). The second patient with PCD had 
DNAH5, DNALI1 and GAS8 present, however, inconclusive results were obtained by 
immunofluorescence for RSPH4A on two separate slides and the other radial spoke head 
proteins RSPH1 and RSPH9 were absent. This patient had a circular beat pattern on light 
microscopy and a transposition /central pair complex defect detected by electron microscopy. 
These insufficient and inconclusive patients were excluded from the sensitivity and 
specificity analysis, inclusion of these inconclusive results as ‘missed cases’ modifies the 
sensitivity to 81% but does not affect the specificity. In thirty five patients a diagnosis of 
‘PCD positive’ or ‘PCD negative’ could not be reached during the study period.  
 
We investigated factors relating to insufficient and inconclusive immunofluorescent results. 
Blood and mucus in the sample both appeared to be confounding factors. In 63% of samples 
with inconclusive results by immunofluorescence viscous mucus was surrounding the cilia on 
the high speed video light microscopy assessment compared to 46% of conclusive samples 
(p<0.05). In 25% of samples insufficient for immunofluorescence blood was seen in the 
sample compared to 8% in sufficient samples (p<0.01). The cause of this relationship is 
unknown, we hypothesise that increased blood could prevent cells from attaching to the slides 
or increased blood in a sample is due to a damaged mucosa denuded of cilia as a result of a 
recent infective or inflammatory process 
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Samples were deemed insufficient or inconclusive if a result could not be obtained for one or 
more antibodies. 30% were inconclusive or insufficient in just one antibody, 16% in two 
antibodies and 54% in three or more antibodies. Couriered and cultured samples showed 
similar results compared to nasal brushings taken on site. 
 
Time for results to be available and cost of investigation 
Immunofluorescence was compared to electron microscopy. The turnaround time, defined as 
time from the sample being taken to the results being reported was median 14 days (range 1 - 
40) for immunofluorescence compared to 27 days (range 9 - 61) for electron microscopy 
p<0.05.  Additionally a cost assessment exercise which included staff hours, equipment 
running costs and consumables showed that the cost per sample was $187 for 
immunofluorescence and $1452 for electron microscopy.  The assessment did not include the 
purchase and set up of equipment required. 
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DISCUSSION 
All defects were correctly identified by immunofluorescence in a cohort of patients with a 
known ultrastructural diagnosis of PCD.  In a subsequent cohort of consecutively referred 
patients immunofluorescence successfully identified 22 of 25 patients diagnosed with PCD 
and 252 of 252 in whom the diagnosis was excluded. The sensitivity and specificity of 
immunofluorescence was the same as that of electron microscopy. Immunofluorescence 
failed to identify  12% PCD cases in the present study and is therefore not suitable for use as 
a stand-alone test. This report provides strong evidence for introducing this test into clinical 
practice 
 
The main strength of the immunofluorescence technique is the cost reduction and improved 
turnaround time relative to electron microscopy to confirm a diagnosis of PCD.  The cost of 
the test and the basic equipment and the simplicity of the test may allow improved 
accessibility to a wider population of patients. The immunofluorescence technique also works 
on small samples where there are too few cells to process for electron microscopy analysis. In 
the diagnostic cohort an additional 34 cases could have been diagnosed with the inclusion of 
an immunofluorescence in the diagnostic pathway. 
 
 
The strengths of this study include that it has been conducted in clinical setting which follows 
a nationally audited and standardised algorithm for PCD diagnosis giving a realistic 
indication of how this test performs. . Other strengths include the use of discovery and 
validation cohorts, with large numbers in the latter in particular. 
A weakness of this study, and the field of PCD diagnostics, is the lack of gold standard for 
the diagnosis of PCD.  Despite use of a multidisciplinary diagnosis to maximize diagnostic 
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capability fifteen patients had an indeterminate diagnosis (a situation also seen in cystic 
fibrosis, for example). It is likely that some of these patients have PCD and that our current 
diagnostic protocol has not allowed us to make a firm diagnosis. These cases could have 
PCD, which would impact the sensitivity and specificity of the test; however, this is 
conjectural currently.   
 
The major limitation of the immunofluorescence technique is that the antibodies used are 
directed to specific proteins of interest and therefore defects in unrelated proteins will be 
missed. This antibody panel represents the end products of multiple gene defects, however 
three cases were still missed. The three cases missed in this study had biallelic mutations in 
DNAH11 and HYDIN. This is expected since previous publications have demonstrated the 
outer and inner dynein arms, nexin links and radial spokes are present in patients with these 
defects [15,16]. Antibodies to both HYDIN and DNAH11 proteins are commercially 
available however we have not been able to validate the use of either antibody sufficiently for 
use in PCD diagnosis, nor is there any report in the literature of the successful use of these 
antibodies to identify PCD. New reliable antibodies to the DNAH11 and HYDIN proteins 
would benefit diagnosis and research in this area. Furthermore, the cilium consists of over 
200 proteins and it is therefore likely that other cases of PCD missed by this panel will 
emerge. 
 
Given the similar sensitivity and specificity we envisage that immunofluorescence could be 
useful where transmission electron microscopy equipment or expertise is not available. In 
specialist diagnostic centers where these facilities are available the technique could be added 
to the diagnostic protocol to improve diagnostic success and reduce the number of electron 
microscopy tests required. Application of the immunofluorescence technique in this study 
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was incorporated into our PCD diagnostic pathway following light microscopy assessment.   
Firstly, a core panel of three antibodies is applied and then a second panel based on the 
primary panel and the light microscopy findings. This two-step protocol allows cost, time and 
tissue savings but introduces a selection bias. In this study three patients were diagnosed 
using the second panel by the GAS8 antibody. As absence of DNALI1 always co-existed 
with absence of GAS8 or DNAH5 we suggest DNALI1 might be substituted for GAS8 in the 
first panel. Recent data show that use of a RSPH9 antibody may detect a broader range of 
central pair complex defects than RSPH4A [17]. Therefore GAS8, DNAH5 and RSPH9 
might be a more appropriate selection for the first panel. 
In conclusion immunofluorescence is a useful diagnostic test for PCD, reduces the need for 
repeat biopsies, and improves turnaround time without compromising diagnostic accuracy. 
We suggest it should be included in the routine PCD diagnostic pathway.  
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FIGURE LEGENDS 
Figure 1: Diagram of the ultrastructure of a motile cilium in transverse section. Labels 
indicate ultrastructural features targeted by immunofluorescence with corresponding 
antibodies (bold text). 
 
Figure 2; Workflow diagram indicating the pathway of patients from referral to diagnosis 
during the study period. Numbers in bold indicate the number of patients at each stage of the 
study (not the number of samples). Excluded groups are indicated in red. Groups included in 
the sensitivity and specificity analysis are indicated in green. 
 
Figure 3: Example results in PCD and non PCD samples for three antibodies used in the 
immunofluorescence panel. The left column shows the cell nucleus in blue by DAPI, the next 
column shows presence of cilia on the cell in green by acetylated tubulin. The third column 
shows the protein of interest in red and the final column a merged image of the three 
channels. In the merged image yellow suggests co-localisation and presence of the protein of 
interest, green suggests absence of the protein of interest. The top images show DNALI1 (an 
inner dynein arm component), the middle images DNAH5 (an outer dynein arm component), 
and the bottom RSPH4A (a radial spoke head component) 
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TABLES 
Ultrastructural 
Defect 
Gene Immunofluorescence 
Outer dynein arm 
defect 
DNAH5 DNAH5 Absent 
DNAI1 
ARMC4 
CCDC114 
TXNDC3 
(NME8) 
DNAI2 
DNAL1 
CCDC151 
   
Inner and outer 
dynein arm defect 
C21orf59 DNAH5 Absent 
DNALI1 Absent ZYMND10 
CCDC103 
DNAFF2 
(KTU) 
DNAFF1 
(LRRC50) 
LRRC6 
DNAFF3 
(C19orf31) 
HEATR2 
DYX1C1 
SPAG1 
   
Central complex / 
transposition defect 
RSPH4A RSPH9, 
RSPH4A,RSPH1 
absent 
RSPH9 RSPH9 absent 
RSPH1 RSPH9, RSPH1 absent 
RSPH3 All present 
   
Microtubular 
disorganisation 
with loss of inner 
dynein arm 
CCDC39 DNALI1 Absent 
GAS 8 Absent CCDC40 
   
Microtubular 
disorganisation 
with present  inner 
dynein arms 
CCDC65 GAS 8 Absent 
CCDC164 
GAS8 
   
Normal ciliary 
ultrastructure 
HYDIN All present 
DNAH11 
OFD1 
RPGR 
   
Ciliary ‘aplasia’  CCNO All present 
MCIDAS 
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Table 1: The major classes of ultrastructural defects seen in PCD and the gene associated 
with each defect (former gene name is shown in brackets). Column three shows the assumed 
coverage of the six antibodies investigated in this study over the known ultrastructural and 
gene defects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Immunofluorescence antibody results from 35 patients with primary ciliary 
dyskinesia due to a known ultrastructural defect 
 
 
 
 
 
Electron 
microscopy defect 
 
Absent or 
mislocalised  
antibody 
 
Number of 
patients with 
PCD tested 
(total n=35) 
Outer dynein arm 
defect 
 
DNAH5 14 
Outer and inner 
dynein arm defect 
 
DNAH5   
DNALI1 
10 
Inner dynein arm 
and microtubular 
disorganisation 
defect 
 
DNALI1  GAS8 7 
Transposition defect 
/ central pair 
absence 
RSPH4A 
RSPH9 RSPH1 
4 
Standard diagnosis 
PCD 
positive 
PCD 
negative 
Im
m
u
n
o
fl
u
o
re
s
c
e
n
c
e
 
d
ia
g
n
o
s
is
 PCD positive 22 0 
PCD negative 3 252 
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Table 3: Diagnostic outcome table comparing immunofluorescence technique to the standard 
diagnostic approach in 271 patients referred to a national referral centre for investigation into 
symptoms suggestive of primary ciliary dyskinesia (PCD)
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Electron microscopy
Ciliary Beat Pattern
CBF Hz 
mean 
(stdev) DNAH5 DNALI1 RSPH4A GAS8 RSPH9 RSPH1
PCD negative 148
stiff areas (116), slow beat (87), possible 
area of circling/ semi circling (11), un co-
ordinated (41), dyskinetic (28), fast beat 
(4),static areas (9)* 9.8 (2.1)
Normal ultrastructure -97% both 
dynein arms present (+/- 7%) 89% 
normal microtubular arrangement 
(+/-6%)
present 
(148)
present 
(148)
present 
(148)
present 
(37)
present 
(11)
present 
(11)
n= 252 104 normal beat pattern 11.1 (1.4) ND
present 
(104)
present 
(104)
present 
(104)
ND ND ND
10.2 (2.0)
PCD positive
8
completely static (7), mostly static some 
moving cilia (1)
0Hz-8.4Hz
IDA and ODA defect
absent 
(8)
absent 
(7) 
partial 
absent 
(1)
present 
(8)
present 
(8)
ND ND
n=25
8
completely static (1), static with 
occasional cilia with residual 'twitching or 
slow beat (7) 0Hz
ODA defect
absent 
(8)
present 
(8)
present 
(8)
ND ND ND
2
stiff (1), stiff incomplete beat with static 
patches (1) 4.77Hz*
IDA and MTD defect
present 
(2)
absent   
(2)  
present 
(2)
absent 
(2)
ND ND
1
dyskinesia, circling pattern viewed from 
above 8.4Hz
Transposition defect
present 
(1)
present 
(1)
absent 
(1)
present 
(1)
absent 
(1)
absent 
(1)
3
stiff incomplete beat (3), pause in beat (2) 12.5-13.3Hz
MTD defect
present 
(3)
present 
(3)
present 
(3)
absent 
(3)
present 
(3)
present 
(3)
3
mostly static (1), stiff (3), jittering (3), 
hyperfrequent (1), movement at tips 
static at base (2), incomplete beat(3) 0-16.4Hz
Normal ultrastructure
present 
(3)
present 
(3)
present 
(3)
present 
(3)
present 
(3)
present 
(3)
4.5 (5.1)
Light microscopy
MDT diagnosis 
Immunofluorescence 
 
         Table 4: Comparison of results from light microscopy, electron microscopy and immunofluorescence testing of nasal brushings from patients referred 
due to clinical symptoms suggestive of primary ciliary dyskinesia. CBF = ciliary beat frequency *one patient in this group did not have CBF measured due 
to dyskinesia  
